New research from Harvard economist Rebecca Diamond suggests a notable link between weight-loss drug use and employment status for women. The study highlights that unemployed women who began a GLP-1 regimen saw a 27 percentage point increase in employment after 18 months. This data points toward an obesity penalty in the hiring process, where heavier women face significant barriers to finding work compared to their peers.
The findings confirm a long-standing observation that appearance impacts career outcomes. Women who utilized these medications also reported a 29 percentage point increase in marriage and cohabitation rates during the same period. This suggests that the impact of these treatments extends beyond the office and into broader social dynamics.
Despite these gains for job seekers, the research shows no corresponding career advancement for women who were already employed at the time they started the medication. Career trajectories for those already in the workforce remained steady, suggesting the bias is most potent during the initial recruitment phase rather than during internal performance reviews or promotion cycles.
The study also highlights concerns regarding access to medical weight-loss treatments. As early users of these drugs are often financially advantaged, there is a risk that the ability to avoid social and economic penalties becomes limited to those who can afford the out-of-pocket costs or secure coverage. This creates a cycle where medical intervention serves as a potential gatekeeper for career and social stability.